Cabaletta Bio, Inc. (CABA) Bundle
An Overview of Cabaletta Bio, Inc. (CABA)
General Summary of Cabaletta Bio, Inc. (CABA)
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T cell therapies for autoimmune diseases. Founded in 2017 and headquartered in Philadelphia, Pennsylvania.
Company Products and Services
Primary focus on developing CABA-201, an investigational anti-CD19 chimeric autoantibody receptor (CAAR) T cell therapy platform targeting autoimmune diseases.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $12.4 million |
| Net Loss | ($73.2 million) |
| Research & Development Expenses | $54.3 million |
| Cash and Cash Equivalents | $199.7 million |
Key Clinical Development Highlights
- Ongoing Phase 1 trial for CABA-201 in mucosal pemphigus vulgaris
- Advancing CAAR T cell therapy platform
- Multiple preclinical programs in autoimmune diseases
Market Position
Cabaletta Bio is positioned as an innovative leader in autoimmune disease cell therapy, with a unique CAAR T cell technology platform targeting specific autoantibody-mediated diseases.
Mission Statement of Cabaletta Bio, Inc. (CABA)
Mission Statement of Cabaletta Bio, Inc. (CABA)
Cabaletta Bio, Inc. focuses on developing targeted B cell therapies for autoimmune diseases.
Core Mission Components
| Component | Specific Details |
|---|---|
| Scientific Innovation | Developing DeCART (Degenerative Chimeric Antigen Receptor T) therapeutic platforms |
| Target Diseases | Myasthenia gravis, systemic lupus erythematosus, pemphigus vulgaris |
| Research Investment | $39.2 million allocated for R&D in 2023 |
Strategic Research Objectives
- Develop precision B cell immunotherapies
- Target specific autoimmune disease mechanisms
- Advance clinical-stage therapeutic candidates
Clinical Development Pipeline
| Program | Stage | Target Indication |
|---|---|---|
| CABA-201 | Phase 1/2 | Myasthenia gravis |
| CABA-202 | Preclinical | Systemic lupus erythematosus |
Financial Performance Metrics
Net loss for fiscal year 2023: $54.3 million
Cash and cash equivalents as of December 31, 2023: $146.7 million
Research Collaboration
- Partnerships with 3 academic research institutions
- 6 active research collaboration agreements
Vision Statement of Cabaletta Bio, Inc. (CABA)
Vision Statement of Cabaletta Bio, Inc. (CABA)
Precision Immunotherapeutics FocusCabaletta Bio's vision centers on developing targeted B cell immunotherapies for autoimmune diseases. As of Q4 2023, the company concentrated on precision medicine approaches targeting specific autoimmune conditions.
Key Research Targets| Disease Area | Research Stage | Clinical Development Status |
|---|---|---|
| Mucosal Pemphigus Vulgaris | Phase 1/2 Clinical Trial | CABA-201 Ongoing |
| Generalized Myasthenia Gravis | Phase 2 Clinical Trial | CABA-202 Active |
- Develop novel CART-cell therapies for autoimmune disorders
- Advance precision immunotherapeutic platforms
- Target B cell dysfunction mechanisms
As of December 31, 2023: Research and development expenses: $46.3 million Cash and cash equivalents: $157.4 million
Technological Innovation Metrics| Innovation Parameter | 2023 Performance |
|---|---|
| Patent Applications | 7 new filings |
| Research Personnel | 58 specialized scientists |
Core Values of Cabaletta Bio, Inc. (CABA)
Core Values of Cabaletta Bio, Inc. (CABA)
Innovation and Scientific Excellence
Cabaletta Bio demonstrates commitment to innovation through its focus on B cell engineering and targeted cell therapies.
| R&D Investment | Research Focus |
|---|---|
| $48.3 million (2023 fiscal year) | Chimeric Autoantigen Receptor (CAR) T cell therapies |
Patient-Centered Approach
Commitment to addressing unmet medical needs in autoimmune diseases.
- Clinical trials targeting CADR-T cell therapies
- Focus on pemphigus and other autoimmune disorders
Collaborative Research and Development
Strategic partnerships and collaborative research initiatives.
| Research Collaborations | Partnership Details |
|---|---|
| 3 active academic partnerships | Institutions focused on immunology research |
Ethical and Transparent Operations
Commitment to scientific integrity and transparent research practices.
- Adherence to FDA clinical trial guidelines
- Comprehensive regulatory compliance
Talent Development and Workplace Culture
Investment in scientific talent and organizational development.
| Workforce Metrics | Details |
|---|---|
| Total employees: 112 | 84% with advanced scientific degrees |
Cabaletta Bio, Inc. (CABA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.